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Editorial
Indications for hematopoietic cell
transplantation for children with severe
congenital neutropenia
Severe congenital neutropenia (SCN) is a hema-
tologic condition characterized by arrested mat-
uration of myelopoiesis at the promyelocyte
stage of development (1). With appropriate
treatment using recombinant human granulocyte
colony-stimulating factor (r-HuG-CSF), patients
with SCN are now surviving well past infancy.
With longer survival, the high risk of developing
myelodysplastic syndrome (MDS)/acute myeloid
leukemia (AML) has become remarkedly clear
(2). Hematopoietic cell transplant (HCT) is the
only curative option for these patients, but the
outcome is poor once MDS/AML has developed.
In this issue of the journal, Oshima et al. (3)
report an analysis of 18 patients with SCN in
Japan who underwent HCT (1989–2005) because
of the lack of or a partial response to treatment
with r-HuG-CSF prior to malignant transforma-
tion to MDS/AML.
Patients with high-risk SCN
All patients with SCN are at risk of developing
MDS/AML at a rate of approximately 2.3% per
year after 10 yr on r-HuG-CSF. This was
recently reported in the British Journal of Hema-
tology by Rosenberg et al. (4), which is substan-
tially below the range of 4–12% per year
suggested by previous Severe Congenital Neu-
tropenia International Registry (SCNIR) data.
Nonetheless, the cumulative incidence for sepsis
death and malignant transformation in high-risk
patients (median absolute neutrophil count
[ANC] remains consistently <2.19 · 109/L de-
spite being on r-HuG-CSF >8 lg/kg/day) after
15 yr is 18% and 34%, respectively. These
median values (8 lg/kg/day and 2.19 · 109/L)
are based upon previously described interactions
between the dose of r-HuG-CSF at six months
and the ANC value on treatment and reflect
somewhat higher target values than recom-
mended today (5). Once the high-risk patients
are identified, we believe that transplant with the
best available donor is the treatment of choice.
Initially, the majority of patients who underwent
HCT received bone marrow from HLA-matched
siblings, but the number of patients undergoing
transplantation from alternative donors (haplo-
identical, unrelated adult donors, and unrelated
cord blood transplants) is growing (6). Once
patients with SCN go on to develop MDS/AML,
the prognosis is dismal with mortality rates
approaching 100%. Although remissions can be
achieved with chemotherapy, serious infectious
complications are common, and adequate neu-
trophil recovery can only be reliably achieved
with reinstitution of r-HuG-CSF. Survival in
patients who transform to malignancy therefore
is dependent on undergoing a successful alloge-
neic HCT. We previously reported on six patients
who underwent transplant for leukemic transfor-
mation and their outcomes (7). Patients who
progressed to AML before transplant were at
high risk of transplant-related complications and
experienced high rates of mortality. Patients with
high-risk SCN who undergo allogeneic HCT
prior to leukemic transformation have had the
best outcomes. Thus, it is imperative to identify
these high-risk patients early and refer them for
consideration of allogeneic HCT. At our own
institution, five of the six patients who underwent
transplant for lack of response to r-HuG-CSF
remain alive with a median of 7.15 yr.
Patients with low-risk SCN
In patients who receive r-HuG-CSF lower than
8 lg/kg/day and achieve a median ANC above
2.19 · 109/L (low-risk group), referral for bone
marrow transplant consult should still be made




early in the treatment course because the cumu-
lative incidence of malignant transformation still
attains high levels. If a matched related donor is
identified, proceeding with transplant should be
considered, especially with the improved sup-
portive care and transplant-related outcomes.
This approach is similar to that taken for
patients with b-thalassemia, for whom related
donor transplant is the standard of care before
serious complications have an opportunity to
develop. For patients with SCN without an
available related donor, close monitoring with
routine complete blood counts and annual bone
marrow examinations, including cytogenetic
studies is essential. At this time, data are lacking
to recommend up-front alternative donor trans-
plantation for patients with low-risk SCN.
The relative hazard curve for malignant trans-
formation for those patients who are able to
maintain a median ANC between 1.0 and
1.5 · 109/L with daily r-HuG-CSF dosing
<8 lg/kg/day is not known. We suspect that it
probably falls somewhere between the low- and
high-risk groups. The initial analysis from the
SCNIR targeted a median ANC above or below
2.19 · 109/L to confer risk stratification, low
versus high groups, respectively (5). However,
when the initial cohort was treated with r-HuG-
CSF, the target ANC was higher than current
standard practice, hence a relatively high median
ANC. Therefore, similar to the approach for the
low-risk group, we recommend early referral to a
blood and marrow transplant team for these
patients and if a matched related donor is
identified, transplant should be considered.
Conditioning regimen and graft-versus-host disease
(GVHD) prophylaxis
Optimal pretransplant conditioning and GVHD
prophylaxis have not been established for pa-
tients with SCN. In the Oshima analysis, there
was considerable heterogeneity in approaches
(3). Twelve patients received a myeloablative
conditioning regimen, and six patients received a
non-myeloablative conditioning regimen. There
were no statistically significant differences in
survival rates between the two groups. However,
based on this limited number of patients, there is
insufficient experience to suggest that non-my-
eloablative transplants should be the preferred
conditioning regimen. As the authors pointed
out, in the absence of leukemic transformation,
patients with SCN typically do not receive
chemotherapy prior to undergoing allogeneic
HCT and thus have an intact T-cell repertoire.
Thus, an immunoablative regimen appears to be
the important factor to take into consideration in
choosing the appropriate conditioning, i.e., some
sort of anti-T-cell therapy, such as anti-thymo-
cyte globulin (ATG), because of the increased
risk for rejection. The high rate of graft rejection
observed by Oshima et al. (3) emphasizes this
point. None of the patients who rejected their
grafts received ATG in their conditioning regi-
men. With the increasing number of agents with
immunosuppressive and myelosuppressive activ-
ity, the options for conditioning regimens have
broadened. Thus, it is not possible to recom-
mend a single conditioning regimen for all
patients with SCN who undergo allogeneic
HCT. Patient age, comorbidities, degree of
human leukocyte antigen matching, and donor
source are important factors to take into con-
sideration when selecting a conditioning regi-
men. Additional factors that contribute to
successful engraftment following allogeneic
HCT include cell dose, prior treatment, and
post-transplant GVHD prophylaxis. We agree
with the authors that GVHD prophylaxis should
be optimized in patients with SCN undergoing
transplant because they do not benefit from any
graft-versus-leukemia effects if they have not
transformed to MDS/AML. At present, we
recommend that institutional practice guides
the choice of conditioning regimen and GVHD
prophylaxis.
Summary
Allogeneic HCT is reserved for patients with
SCN to high-risk patients and/or once MDS or
AML develops. In these patients, allogeneic
transplant with the best matched donor has
evolved into a standard of care. Over time, with
our improved understanding of the disease, the
timing of transplantation for patients with high-
risk SCN has moved earlier in the course of
illness, and outcomes are better for patients
transplanted prior to malignant transformation.
For low-risk patients, if a related donor is
available, consideration to proceed with alloge-
neic HCT should be made with a careful
balancing of short- and long-term risk of HCT
against the cumulative risk of death from malig-
nant transformation. If a related donor is not
available, balancing the known lifetime risk of
leukemic transformation against the morbidity
and mortality risk of allogeneic transplantation
remains a challenge. At present, for most patients
with r-HuG-CSF-responsive SCN, continued
treatment with r-HuG-CSF will be favored over
alternative donor allogeneic HCT. However, as
the risk of treatment-related mortality continues
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to be successfully reduced with improved strat-
egies and supportive care measures, we expect to
see more alternative donor transplants for
patients with SCN.
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